At a glance
ClinicalIndex Comparison Record- ✓Age 13 years or older
- ✓Best-corrected visual acuity of hand motions or better in at least one eye with uveitis
- ✓Intraocular pressure 24 mm Hg or less in all eyes with uveitis
- ✕Inadequately controlled diabetes
- ✕Uncontrolled glaucoma
- ✕Advanced glaucomatous optic nerve injury
- ✕History of scleritis or presence of ocular toxoplasmosis scar
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Uveitis Steroid Treatment (MUST) Trial
In Brief
A Phase 4 clinical trial evaluating fluocinolone acetonide intraocular implant and oral corticosteroid with immunosuppressive agents as needed for Uveitis. Completed, enrolled 255 participants across 23 sites in 3 countries.
Detailed Summary
The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
Study Details
Timeline
Interventions
RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
Prednisone